 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Emcyt, Estracyt |
| Other names | EMP; Leo 299; NSC-89199; Ro 21-8837/001; Estradiol normustine phosphate; Estradiol 3-normustine 17β-phosphate; Estradiol 3-(bis(2-chloroethyl)carbamate) 17β-(dihydrogen phosphate) |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a608046 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth, IV |
| Drug class | Chemotherapeutic agent; Estrogen; Estrogen ester |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 44–75% (as estramustine and estromustine)[1] |
| Protein binding | • Estradiol: 98%[2] • Estrone: 96%[2] |
| Metabolism | Liver, intestines[3][1][4] |
| Metabolites | • Estramustine[3][1] • Estromustine[3][1] • Estradiol[3][1] • Estrone[3][1] • Phosphoric acid[3][1] • Normustine[5] |
| Elimination half-life | • EMP: 1.27 hours[6] • Estromustine: 10–14 hrs[1] • Estrone: 15–17 hours[1] |
| Excretion | Bile, feces (2.9–4.8%)[1][4] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.023.193 |
| Chemical and physical data | |
| Formula | C23H32Cl2NO6P |
| Molar mass | 520.38 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Estramustine phosphate (EMP), also known as estradiol normustine phosphate and sold under the brand names Emcyt and Estracyt, is a dual estrogen and chemotherapy medication which is used in the treatment of prostate cancer in men.[7][5][8][9][10][3][1][11][6][12] It is taken multiple times a day by mouth or by injection into a vein.[7][8][3][1][6][12]
Side effects of EMP include nausea, vomiting, gynecomastia, feminization, demasculinization, sexual dysfunction, blood clots, and cardiovascular complications.[3][9][13] EMP is a dual cytostatic and hence chemotherapeutic agent and a hormonal anticancer agent of the estrogen type.[1][3][14][6] It is a prodrug of estramustine and estromustine in terms of its cytostatic effects and a prodrug of estradiol in relation to its estrogenic effects.[1][3] EMP has strong estrogenic effects at typical clinical dosages, and consequently has marked antigonadotropic and functional antiandrogenic effects.[5][1][3][14]
EMP was introduced for medical use in the early 1970s.[3] It is available in the United States, Canada, the United Kingdom, other European countries, and elsewhere in the world.[15][16]
Medical uses
EMP is indicated, in the United States, for the palliative treatment of metastatic and/or progressive prostate cancer,[4] whereas in the United Kingdom it is indicated for the treatment of unresponsive or relapsing prostate cancer.[17][6][1][10] The medication is usually reserved for use in hormone-refractory cases of prostate cancer, although it has been used as a first-line monotherapy as well.[3] Response rates with EMP in prostate cancer are said to be equivalent to conventional high-dose estrogen therapy.[18]
Due to its relatively severe side effects and toxicity, EMP has rarely been used in the treatment of prostate cancer.[5] This is especially true in Western countries today.[5] As a result, and also due to the scarce side effects of gonadotropin-releasing hormone modulators (GnRH modulators) like leuprorelin, EMP was almost abandoned.[3] However, encouraging clinical research findings resulted in renewed interest of EMP for the treatment of prostate cancer.[3]
EMP has been used at doses of 140 to 1,400 mg/day orally in the treatment of prostate cancer.[19] However, oral EMP is most commonly used at a dose of 560 to 640 mg/day (280–320 mg twice daily).[1] The recommended dosage of oral EMP in the Food and Drug Administration (FDA) label for Emcyt is 14 mg per kg of body weight (i.e., one 140 mg oral capsule for each 10 kg or 22 lbs of body weight) given in 3 or 4 divided doses per day.[7] The label states that most patients in studies of oral EMP in the United States have received 10 to 16 mg per kg per day.[7] This would be about 900 to 1,440 mg/day for a 90-kg or 200-lb man.[7] Lower doses of oral EMP, such as 280 mg/day, have been found to have comparable effectiveness as higher doses but with improved tolerability and reduced toxicity.[5] Doses of 140 mg/day have been described as a very low dosage.[20] EMP has been used at doses of 240 to 450 mg/day intravenously.[1]
EMP and other estrogens such as polyestradiol phosphate and ethinylestradiol are far less costly than newer therapies such as GnRH modulators, abiraterone acetate, and enzalutamide.[5][21][22] In addition, estrogens may offer significant benefits over other means of androgen deprivation therapy, for instance in terms of bone loss and fractures, hot flashes, cognition, and metabolic status.[5][22]
EMP has been used to prevent the testosterone flare at the start of GnRH agonist therapy in men with prostate cancer.[23]
| Route/form | Estrogen | Dosage | |
|---|---|---|---|
| Oral | Estradiol | 1–2 mg 3x/day | |
| Conjugated estrogens | 1.25–2.5 mg 3x/day | ||
| Ethinylestradiol | 0.15–3 mg/day | ||
| Ethinylestradiol sulfonate | 1–2 mg 1x/week | ||
| Diethylstilbestrol | 1–3 mg/day | ||
| Dienestrol | 5 mg/day | ||
| Hexestrol | 5 mg/day | ||
| Fosfestrol | 100–480 mg 1–3x/day | ||
| Chlorotrianisene | 12–48 mg/day | ||
| Quadrosilan | 900 mg/day | ||
| Estramustine phosphate | 140–1400 mg/day | ||
| Transdermal patch | Estradiol | 2–6x 100 μg/day Scrotal: 1x 100 μg/day | |
| IM or SC injection | Estradiol benzoate | 1.66 mg 3x/week | |
| Estradiol dipropionate | 5 mg 1x/week | ||
| Estradiol valerate | 10–40 mg 1x/1–2 weeks | ||
| Estradiol undecylate | 100 mg 1x/4 weeks | ||
| Polyestradiol phosphate | Alone: 160–320 mg 1x/4 weeks With oral EE: 40–80 mg 1x/4 weeks | ||
| Estrone | 2–4 mg 2–3x/week | ||
| IV injection | Fosfestrol | 300–1200 mg 1–7x/week | |
| Estramustine phosphate | 240–450 mg/day | ||
| Note: Dosages are not necessarily equivalent. Sources: See template. | |||
Available forms
EMP is or has been available in the form of both capsules (140 mg, 280 mg) for oral administration and aqueous solutions (300 mg) for intravenous injection.[19][24][25][7]
Contraindications
EMP is contraindicated when used in children, patients hypersensitive to estrogens or nitrogen mustards, those with peptic ulcer (an ulcer in the digestive tract), those with severely compromised liver function, those with weak heart muscle (also known as myocardial insufficiency) and those with thromboembolic disorders or complications related to fluid retention.[17]
Side effects
The side effects of EMP overall have been described as relatively severe.[3] The most common side effects of EMP have been reported to be gastrointestinal side effects like nausea, vomiting, and diarrhea, with nausea and vomiting occurring in 40% of men.[9][1] They are usually mild or moderate in severity, and the nausea and vomiting can be managed with prophylactic antiemetic medications.[9] Nonetheless, severe cases of gastrointestinal side effects with EMP may require dose reduction or discontinuation of therapy.[1] Although nausea and vomiting have been reported to be the most common side effects of EMP, gynecomastia (male breast development) has been found to occur in as many as 83% of men treated with EMP, and the incidence of erectile dysfunction is possibly similar to or slightly less than the risk of gynecomastia.[3] As a rule, feminization, a gynoid fat distribution, demasculinization, and impotence are said to occur in virtually or nearly 100% of men treated with high-dose estrogen therapy.[13][26] Decreased sexual activity has also been reported in men treated with EMP.[1] These side effects are due to high estrogen levels and low testosterone levels.[1][3] Prophylactic irradiation of the breasts can be used to decrease the incidence and severity of gynecomastia with estrogens.[13]
Severe adverse effects of EMP are thromboembolic and cardiovascular complications including pulmonary embolism, deep vein thrombosis, stroke, thrombophlebitis, coronary artery disease (ischemic heart disease; e.g., myocardial infarction), thrombophlebitis, and congestive heart failure with fluid retention.[9][1] EMP produces cardiovascular toxicity similarly to diethylstilbestrol, but to a lesser extent in comparison at low doses (e.g., 280 mg/day oral EMP vs. 1 mg/day oral diethylstilbestrol).[3][27] The prostate cancer disease state also increases the risk of thromboembolism, and combination with docetaxel may exacerbate the risk of thromboembolism as well.[9] Meta-analyses of clinical trials have found that the overall risk of thromboembolism with EMP is 4 to 7%, relative to 0.4% for chemotherapy regimens without EMP.[9][28] Thromboembolism is the major toxicity-related cause of discontinuation of EMP.[29] Anticoagulant therapy with medications such as aspirin, warfarin, unfractionated and low-molecular-weight heparin, and vitamin K antagonists can be useful for decreasing the risk of thromboembolism with EMP and other estrogens like diethylstilbestrol and ethinylestradiol.[9][30][5]
Adverse liver function tests are commonly seen with EMP, but severe liver dysfunction is rare with the medication.[1] Central nervous system side effects are rarely seen with EMP, although enlarged ventricles and neuronal pigmentation have been reported in monkeys treated with very high doses of EMP (20–140 mg/kg/day) for 3 to 6 months.[1] EMP does not appear to have cytostatic effects in normal brain tissue.[1] In women treated with EMP in clinical studies, a few instances of minor gynecological hemorrhages have been observed.[1] EMP is described as relatively well tolerated among cytostatic antineoplastic and nitrogen-mustard agents, rarely or not at all being associated with significant hematologic toxicity such as myelosuppression (bone marrow suppression), gastrointestinal toxicity, or other more marked toxicity associated with such agents.[6][1][31] In contrast to most other cytostatic agents, which often cause myelosuppression, leukopenia (decreased white blood cell count), and neutropenia (decreased neutrophil count), EMP actually produces leukocytosis (increased white blood cell count) as a side effect.[32][33]
In a small low-dose study using 280 mg/day oral EMP for 150 days, tolerability was significantly improved, with gastrointestinal irritation occurring in only 15% of men, and there was no incidence of severe cardiovascular toxicity or deep vein thrombosis.[3][5] In addition, no other side effects besides slight transient elevated liver enzymes were observed.[3] These findings suggest that lower doses of oral EMP may be a safer option than higher doses for the treatment of prostate cancer.[5] However, a subsequent 2004 meta-analysis of 23 studies of thromboembolic events with EMP found substantial incidence of thromboembolic events regardless of dosage and no association of EMP dose with risk of these complications.[28]
Overdose
There has been no clinical experience with overdose of EMP.[7] Overdose of EMP may result in pronounced manifestations of the known adverse effects of the medication.[7] There is no specific antidote for overdose of EMP.[17] In the event of overdose, gastric lavage should be used to evacuate gastric contents as necessary and treatment should be symptom-based and supportive.[7][17] In the case of dangerously low counts of red blood cells, white blood cells, or platelets, whole blood may be given as needed.[17] Liver function should be monitored with EMP overdose.[17] After an overdose of EMP, hematological and hepatic parameters should continue to be monitored for at least 6 weeks.[7]
EMP has been used at high doses of as much as 1,260 mg/day by the oral route and 240 to 450 mg/day by intravenous injection.[3][1]
Interactions
EMP has been reported to increase the efficacy and toxicity of tricyclic antidepressants like amitriptyline and imipramine.[17] When products containing calcium, aluminium, and/or magnesium, such as dairy products like milk, various foods dietary supplements, and antacids, are consumed concomitantly with EMP, an insoluble chelate complex/phosphate salt between EMP and these metals can be formed, and this can markedly impair the absorption and hence oral bioavailability of EMP.[3][1][17] There may be an increased risk of angioedema in those concurrently taking ACE inhibitors.[17]
Pharmacology
Pharmacodynamics
EMP, also known as estradiol normustine phosphate, is a combined estrogen ester and nitrogen mustard ester.[1][3][14] It consists of estradiol, an estrogen, linked with a phosphate ester as well as an ester of normustine, a nitrogen mustard.[1][3][14] In terms of its pharmacodynamic effects, EMP is a prodrug of estramustine, estromustine, and estradiol.[1][3] As a prodrug of estradiol, EMP is an estrogen and hence an agonist of the estrogen receptors.[1][2] EMP itself has only very weak affinity for the estrogen receptors.[1] The medication is of about 91% higher molecular weight than estradiol due to the presence of its C3 normustine and C17β phosphate esters.[35][15] Because EMP is a prodrug of estradiol, it may be considered to be a natural and bioidentical form of estrogen,[14] although it does have additional cytostatic activity via estramustine and estromustine.[1][3]
EMP acts by a dual mechanism of action: 1) direct cytostatic activity via a number of actions; and 2) as a form of high-dose estrogen therapy via estrogen receptor-mediated antigonadotropic and functional antiandrogenic effects.[1][3][14] The antigonadotropic and functional antiandrogenic effects of EMP consist of strong suppression of gonadal androgen production and hence circulating levels of androgens such as testosterone; greatly increased levels of sex hormone-binding globulin and hence a decreased fraction of free androgens in the circulation; and direct antiandrogenic actions in prostate cells.[31][1][3][5][36][37][38] The free androgen index with oral EMP has been found to be on average 4.6-fold lower than with orchiectomy.[37] As such, EMP therapy results in considerably stronger androgen deprivation than orchiectomy.[38] Metabolites of EMP, including estramustine, estromustine, estradiol, and estrone, have been found to act as weak antagonists of the androgen receptor (EC50 = 0.5–3.1 μM), although the clinical significance of this is unknown.[39][36][3][1]
Extremely high levels of estradiol and estrone occur during EMP therapy.[3][5] The estrogenic metabolites of EMP are responsible for its most common adverse effects and its cardiovascular toxicity.[1] EMP has been described as having relatively weak estrogenic effects in some publications.[6][31] However, it has shown essentially the same rates and degrees of estrogenic effects, such as breast tenderness, gynecomastia, cardiovascular toxicity, changes in liver protein synthesis, and testosterone suppression, as high-dose diethylstilbestrol and ethinylestradiol in clinical studies.[7][5][31][38][40] The notion that EMP has relatively weak estrogen activity may have been based on animal research, which found that EMP had 100-fold lower uterotrophic effects than estradiol in rats, and may also not have taken into account the very high doses of EMP used clinically in humans.[40][41]
The mechanism of action of the cytostatic effects of EMP is complex and only partially understood.[1] EMP is considered to mainly be a mitotic inhibitor, inhibiting mechanisms involved in the mitosis phase of the cell cycle.[1][5] Specifically, it binds to microtubule-associated proteins and/or to tubulin and produces depolymerization of microtubules (Kd = 10–20 μM for estramustine), resulting in the arrest of cell division in the G2/M phase (specifically metaphase).[1][5][42] EMP was originally thought to mediate its cytostatic effects as a prodrug of normustine, a nitrogen mustard, and hence was thought to be an alkylating antineoplastic agent.[3][10][6][14] However, subsequent research has found that EMP is devoid of alkylating actions, and that the influence of EMP on microtubules is mediated by intact estramustine and estromustine, with normustine or estradiol alone having only minor or negligible effects.[1][3][43] As such, the unique properties of the estramustine and estromustine structures, containing a carbamate-ester bond, appear to be responsible for the cytostatic effects of EMP.[1] In addition to its antimitotic actions, EMP has also been found to produce other cytostatic effects, including induction of apoptosis, interference with DNA synthesis, nuclear matrix interaction, cell membrane alterations, induction of reactive oxygen species (free oxygen radicals), and possibly additional mechanisms.[1][5] EMP has been found to have a radiosensitizing effect in prostate cancer and glioma cells, improving sensitivity to radiation therapy as well.[1]
The cytostatic metabolites of EMP are accumulated in tissues in a selective manner, for instance in prostate cancer cells.[6][1][5] This may be due to the presence of a specific estramustine-binding protein (EMBP) (Kd = 10–35 nM for estramustine), also known as prostatin or prostatic secretion protein (PSP), which has been detected in prostate cancer, glioma, melanoma, and breast cancer cells.[1][5][44] Because of its tissue selectivity, EMP is said to produce minimal cytostatic effects in healthy tissues, and its tissue selectivity may be responsible for its therapeutic cytostatic efficacy against prostate cancer cells.[6][5][1]
EMP was originally developed as a dual ester prodrug of an estrogen and normustine as a nitrogen mustard alkylating antineoplastic agent which, due to the affinity of the estrogen moiety for estrogen receptors, would be selectively accumulated in estrogen target tissues and hence estrogen receptor-positive tumor cells.[5][14][2] Consequentially, it was thought that EMP would preferentially deliver the alkylating normustine moiety to these tissues, allowing for reduced cytostatic effects in healthy tissues and hence improved efficacy and tolerability.[5] However, subsequent research found that there is very limited and slow cleavage of the normustine ester and that EMP is devoid of alkylating activity.[5][1][3][31] In addition, it appears that estramustine and estromustine may be preferentially accumulated in estrogen target tissues not due to affinity for the estrogen receptors, but instead due to affinity for the distinct EMBP.[1][3]
Extremely high, pregnancy-like levels of estradiol may be responsible for the leukocytosis (increased white blood cell count) that is observed in individuals treated with EMP.[32][33] This side effect is in contrast to most other cytotoxic agents, which instead cause myelosuppression (bone marrow suppression), leukopenia (decreased white blood cell count), and neutropenia (decreased neutrophil count).
Antigonadotropic effects
EMP at a dosage 280 mg/day has been found to suppress testosterone levels in men into the castrate range (to 30 ng/dL) within 20 days and to the low castrate range (to 10 ng/dL) within 30 days.[3] Similarly, a dosage of 70 mg/day EMP suppressed testosterone levels into the castrate range within 4 weeks.[3]
Pharmacokinetics
| Parameter | IV 300 mg | Oral 420 mg |
|---|---|---|
| Cmax | 506 ± 61 ng/mL | 362 ± 38 ng/mL |
| Tmax | 2.6 ± 0.4 hours | 2.2 ± 0.2 hours |
| t1/2 | 10.3 ± 0.95 hours | 13.6 ± 3.09 hours |
| AUC0–32 | 4.82 ± 0.62 | 2.88 ± 0.34 |
| Bioavailability | 100.0% | 43.7% ± 4.6% |
| Sources: [31] | ||
| Metabolite | Plasma | Ratio |
|---|---|---|
| Estramustine | 20,000–23,000 pg/mL | 1:9.6–9.8 |
| Estromustine | 191,000–267,000 pg/mL | |
| Estradiol | 4,900–9,000 pg/mL | 1:9.4–11.8 |
| Estrone | 71,000–85,000 pg/mL | |
| Sources: [31] | ||
Upon oral ingestion, EMP is rapidly and completely dephosphorylated by phosphatases into estramustine during the first pass in the gastrointestinal tract.[1][5][6][45] Estramustine is also partially but considerably oxidized into estromustine by 17β-hydroxysteroid dehydrogenases during the first pass.[6][1][12][46] As such, EMP reaches the circulation as estramustine and estromustine, and the major metabolite of EMP is estromustine.[1][12] A limited quantity of approximately 10 to 15% of estramustine and estromustine is further slowly metabolized via hydrolysis of the normustine ester into estradiol and estrone, respectively.[1][5][31] This reaction is believed to be catalyzed by carbamidases, although the genes encoding the responsible enzymes have not been characterized.[1][47][48] The circulating levels of normustine formed from EMP are insignificant.[43][49] Release of nitrogen mustard gas from normustine via cleavage of the carboxylic acid group has not been demonstrated and does not seem to occur.[42][31]
The oral bioavailability of EMP is low, which is due to profound first-pass metabolism; specifically, dephosphorylation of EMP.[1] The oral bioavailability of EMP specifically as estramustine and estromustine is 44 to 75%, suggesting that absorption may be incomplete.[1] In any case, there is a linear relationship between the oral dose of EMP and circulating levels of estramustine and estromustine.[1] Consumption of calcium, aluminium, or magnesium with oral EMP can markedly impair its bioavailability due to diminished absorption from the intestines, and this may interfere with its therapeutic effectiveness at low doses.[3][17]
Following a single oral dose of 420 mg EMP in men with prostate cancer, maximal levels of estromustine were 310 to 475 ng/mL (475,000 pg/mL) and occurred after 2 to 3 hours.[1] Estradiol levels with 280 mg/day oral EMP have been found to increase to very high concentrations within one week of therapy.[3] In one study, levels of estradiol were over 20,000 pg/mL after 10 days, were about 30,000 pg/mL after 30 days, and peaked at about 40,000 pg/mL at 50 days.[3] Another study found lower estradiol levels of 4,900 to 9,000 pg/mL during chronic therapy with 560 mg/day oral EMP.[31] An additional study found estradiol levels of about 17,000 pg/mL with 140 mg/day oral EMP and 38,000 pg/mL with 280 mg/day oral EMP. The circulating levels of estradiol and estrone during EMP therapy have been reported to exceed normal levels in men by more than 100- and 1,000-fold, respectively.[5][31] Levels of estramustine and estradiol in the circulation are markedly lower than those of estromustine and estrone, respectively, with a ratio of about 1:10 in both cases.[1][31] Nonetheless, estradiol levels during EMP therapy appear to be similar to those that occur in mid-to-late pregnancy, which range from 5,000 to 40,000 pg/mL.[50] No unchanged EMP is seen in the circulation with oral administration.[1]
The pharmacokinetics of EMP are different with intravenous injection.[1] Following a single intravenous injection of 300 mg EMP, levels of EMP were higher than those of its metabolites for the first 8 hours.[1] This is likely due to the bypassing of first-pass metabolism.[1] However, by 24 hours after the dose, unchanged EMP could no longer be detected in the circulation.[1] The clearance of EMP from blood plasma is 4.85 ± 0.684 L/h.[1] The volumes of distribution of EMP with intravenous injection were small; under a two-compartment model, the volume of distribution for the central compartment was 0.043 L/kg and for the peripheral compartment was 0.11 L/kg.[1] The plasma protein binding of EMP is high.[1] Estramustine is accumulated in tumor tissue, for instance prostate cancer and glioma tissue, with estramustine levels much higher in these tissues than in plasma (e.g., 6.3- and 15.9-fold, respectively).[1] Conversely, levels of estromustine in tumor versus plasma are similar (1.0- and 0.5-fold, respectively).[1] Estramustine and estromustine appear to accumulate in adipose tissue.[1]
The elimination half-life of estromustine with oral EMP was 13.6 hours on average, with a range of 8.8 to 22.7 hours.[1] Conversely, the elimination half-life of estromustine with intravenous injection was 10.3 hours, with a range of 7.36 to 12.3 hours.[1] For comparison, the corresponding elimination half-lives of estrone were 16.5 and 14.7 hours for oral and intravenous administration, respectively.[1] Estramustine and estromustine are mainly excreted in bile and hence in feces.[1][31] They are not believed to be excreted in urine.[1]
Chemistry
EMP, also known as estradiol 3-normustine 17β-phosphate or as estradiol 3-(bis(2-chloroethyl)carbamate) 17β-(dihydrogen phosphate), is a synthetic estrane steroid and a derivative of estradiol.[35][15] It is an estrogen ester; specifically, EMP is a diester of estradiol with a C3 normustine (nitrogen mustard–carbamate moiety) ester and a C17β phosphate ester.[35][15] EMP is provided as the sodium or meglumine salt.[35][15][24] EMP is similar as a compound to other estradiol esters such as estradiol sulfate and estradiol valerate, but differs in the presence of its nitrogen mustard ester moiety.[35][15] Antineoplastic agents related to EMP, although none of them were marketed, include alestramustine, atrimustine, cytestrol acetate, estradiol mustard, ICI-85966, and phenestrol.[35][15]
Due to its hydrophilic phosphate ester moiety, EMP is a readily water-soluble compound.[51][52][53] This is in contrast to most other estradiol esters, which are fatty acid esters and lipophilic compounds that are not particularly soluble in water.[2] Unlike EMP, estramustine is highly lipophilic, practically insoluble in water, and non-ionizable.[19] The phosphate ester of EMP was incorporated into the molecule in order to increase its water solubility and allow for intravenous administration.[7]
The molecular weight of EMP sodium is 564.3 g/mol, of EMP meglumine is 715.6 g/mol, of EMP is 520.4 g/mol, of estramustine is 440.4 g/mol, and of estradiol is 272.4 g/mol.[54] As a result of these differences in molecular weights, EMP contains about 52%, EMP sodium about 48%, and EMP meglumine about 38% of the amount of estradiol within their structures as does an equal-mass quantity of estradiol.[54]
| Estrogen | Structure | Ester(s) | Relative mol. weight | Relative E2 contentb | log Pc | ||||
|---|---|---|---|---|---|---|---|---|---|
| Position(s) | Moiet(ies) | Type | Lengtha | ||||||
| Estradiol | | – | – | – | – | 1.00 | 1.00 | 4.0 | |
| Estradiol acetate |  | C3 | Ethanoic acid | Straight-chain fatty acid | 2 | 1.15 | 0.87 | 4.2 | |
| Estradiol benzoate |  | C3 | Benzoic acid | Aromatic fatty acid | – (~4–5) | 1.38 | 0.72 | 4.7 | |
| Estradiol dipropionate |  | C3, C17β | Propanoic acid (×2) | Straight-chain fatty acid | 3 (×2) | 1.41 | 0.71 | 4.9 | |
| Estradiol valerate |  | C17β | Pentanoic acid | Straight-chain fatty acid | 5 | 1.31 | 0.76 | 5.6–6.3 | |
| Estradiol benzoate butyrate |  | C3, C17β | Benzoic acid, butyric acid | Mixed fatty acid | – (~6, 2) | 1.64 | 0.61 | 6.3 | |
| Estradiol cypionate |  | C17β | Cyclopentylpropanoic acid | Cyclic fatty acid | – (~6) | 1.46 | 0.69 | 6.9 | |
| Estradiol enanthate |  | C17β | Heptanoic acid | Straight-chain fatty acid | 7 | 1.41 | 0.71 | 6.7–7.3 | |
| Estradiol dienanthate |  | C3, C17β | Heptanoic acid (×2) | Straight-chain fatty acid | 7 (×2) | 1.82 | 0.55 | 8.1–10.4 | |
| Estradiol undecylate |  | C17β | Undecanoic acid | Straight-chain fatty acid | 11 | 1.62 | 0.62 | 9.2–9.8 | |
| Estradiol stearate |  | C17β | Octadecanoic acid | Straight-chain fatty acid | 18 | 1.98 | 0.51 | 12.2–12.4 | |
| Estradiol distearate |  | C3, C17β | Octadecanoic acid (×2) | Straight-chain fatty acid | 18 (×2) | 2.96 | 0.34 | 20.2 | |
| Estradiol sulfate |  | C3 | Sulfuric acid | Water-soluble conjugate | – | 1.29 | 0.77 | 0.3–3.8 | |
| Estradiol glucuronide | | C17β | Glucuronic acid | Water-soluble conjugate | – | 1.65 | 0.61 | 2.1–2.7 | |
| Estramustine phosphated | | C3, C17β | Normustine, phosphoric acid | Water-soluble conjugate | – | 1.91 | 0.52 | 2.9–5.0 | |
| Polyestradiol phosphatee |  | C3–C17β | Phosphoric acid | Water-soluble conjugate | – | 1.23f | 0.81f | 2.9g | |
| Footnotes: a = Length of ester in carbon atoms for straight-chain fatty acids or approximate length of ester in carbon atoms for aromatic or cyclic fatty acids. b = Relative estradiol content by weight (i.e., relative estrogenic exposure). c = Experimental or predicted octanol/water partition coefficient (i.e., lipophilicity/hydrophobicity). Retrieved from PubChem, ChemSpider, and DrugBank. d = Also known as estradiol normustine phosphate. e = Polymer of estradiol phosphate (~13 repeat units). f = Relative molecular weight or estradiol content per repeat unit. g = log P of repeat unit (i.e., estradiol phosphate). Sources: See individual articles. | |||||||||
History
EMP was first synthesized in the mid-1960s and was patented in 1967.[42] It was initially developed for the treatment of breast cancer.[1] The idea for EMP was inspired by the uptake and accumulation of radiolabeled estrogens into breast cancer tissue.[1] However, initial clinical findings of EMP in women with breast cancer were disappointing.[1] Subsequently, radiolabeled EMP was found to be taken up into and accumulated rat prostate gland, and this finding culminated in the medication being repurposed for the treatment of prostate cancer.[1][3] EMP was introduced for medical use in the treatment of this condition in the early 1970s, and was approved in the United States for this indication in 1981.[1][3][55] EMP was originally introduced for use by intravenous injection.[31] Subsequently, an oral formulation was introduced, and the intravenous preparation was almost abandoned in favor of the oral version.[31]
Society and culture
Generic names
EMP is provided as the sodium salt for oral administration, which has the generic names estramustine phosphate sodium (USAN) and estramustine sodium phosphate (BANM, JAN), and as the meglumine salt for intravenous administration, which has the generic name estramustine phosphate meglumine.[24][35][15][56][16] The INNM is estramustine phosphate.[35] The name estramustine phosphate is a contraction of estradiol normustine phosphate.[35][16] EMP is also known by its former developmental code names Leo 299, Ro 21-8837, and Ro 21-8837/001.[35][15][16]
Brand names
EMP is most commonly marketed under the brand names Estracyt and Emcyt, but has also been sold under a number of other brand names, including Amsupros, Biasetyl, Cellmustin, Estramustin HEXAL, Estramustina Filaxis, Estranovag, Multosin, Multosin Injekt, Proesta, Prostamustin, and Suloprost.[15][16][24]
Availability
EMP is marketed in the United States,[57] Canada, and Mexico under the brand name Emcyt, whereas the medication is marketed under the brand name Estracyt in the United Kingdom and elsewhere throughout Europe as well as in Argentina, Chile, and Hong Kong.[15] It has been discontinued in a number of countries, including Australia, Brazil, Ireland, and Norway.[58]
Research
EMP has been studied in the treatment of other cancers such as glioma and breast cancer.[1] It has been found to slightly improve quality of life in people with glioma during the first 3 months of therapy.[1]
References
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 Bergenheim AT, Henriksson R (February 1998). "Pharmacokinetics and pharmacodynamics of estramustine phosphate". Clinical Pharmacokinetics. 34 (2): 163–172. doi:10.2165/00003088-199834020-00004. PMID 9515186. S2CID 1943973.
- 1 2 3 4 5 Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 Kitamura T (February 2001). "Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer". International Journal of Urology. 8 (2): 33–36. doi:10.1046/j.1442-2042.2001.00254.x. PMID 11240822. S2CID 43384150.
- 1 2 3 "Emcyt (estramustine) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 8 February 2014.
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Inoue T (2018). "Role of Estramustine Phosphate and Other Estrogens for Castration-Resistant Prostate Cancer". Hormone Therapy and Castration Resistance of Prostate Cancer. Springer. pp. 249–256. doi:10.1007/978-981-10-7013-6_26. ISBN 978-981-10-7012-9.
- 1 2 3 4 5 6 7 8 9 10 11 12 13 Perry CM, McTavish D (July 1995). "Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer". Drugs & Aging. 7 (1): 49–74. doi:10.2165/00002512-199507010-00006. PMID 7579781. S2CID 36725810.
- 1 2 3 4 5 6 7 8 9 10 11 12 "Emcyt estramustine phosphate sodium capsules" (PDF). FDA. Retrieved 14 March 2022.
- 1 2 Qin Z, Li X, Zhang J, Tang J, Han P, Xu Z, et al. (September 2016). "Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis". Medicine. 95 (39): e4801. doi:10.1097/MD.0000000000004801. PMC 5265899. PMID 27684806.
- 1 2 3 4 5 6 7 8 Ravery V, Fizazi K, Oudard S, Drouet L, Eymard JC, Culine S, et al. (December 2011). "The use of estramustine phosphate in the modern management of advanced prostate cancer". BJU International. 108 (11): 1782–1786. doi:10.1111/j.1464-410X.2011.10201.x. PMID 21756277. S2CID 33456591.
- 1 2 3 Simpson D, Wagstaff AJ (2003). "Estramustine Phosphate Sodium". American Journal of Cancer. 2 (5): 373–390. doi:10.2165/00024669-200302050-00013. S2CID 70507026.
- ↑ Hudes G (February 1997). "Estramustine-based chemotherapy". Seminars in Urologic Oncology. 15 (1): 13–19. PMID 9050135.
- 1 2 3 4 Kreis W (1995). "Estramustine revisited". Concepts, Mechanisms, and New Targets for Chemotherapy. Cancer Treatment and Research. Vol. 78. Springer. pp. 163–184. doi:10.1007/978-1-4615-2007-8_8. ISBN 978-1-4613-5829-9. PMID 8595142.
- 1 2 3 Galbraith SM, Duchesne GM (April 1997). "Androgens and prostate cancer: biology, pathology and hormonal therapy". European Journal of Cancer. 33 (4): 545–554. doi:10.1016/S0959-8049(96)00444-3. PMID 9274433.
- 1 2 3 4 5 6 7 8 Oettel M, Schillinger E (6 December 2012). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 540–. ISBN 978-3-642-60107-1.
- 1 2 3 4 5 6 7 8 9 10 11 Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 406–407. ISBN 978-3-88763-075-1.
- 1 2 3 4 5 "Estramustine Uses, Side Effects & Warnings".
- 1 2 3 4 5 6 7 8 9 10 "Estracyt Capsules - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Pfizer Limited. 12 August 2013. Archived from the original on 22 February 2014. Retrieved 8 February 2014.
- ↑ Lupulescu A (24 October 1990). Hormones and Vitamins in Cancer Treatment. CRC Press. pp. 40–. ISBN 978-0-8493-5973-6.
- 1 2 3 Stella V, Borchardt R, Hageman M, Oliyai R, Maag H, Tilley J, eds. (12 March 2007). Prodrugs: Challenges and Rewards. Springer Science & Business Media. pp. 174–. ISBN 978-0-387-49782-2.
- ↑ Kitamura T, Suzuki M, Nishimatsu H, Kurosaki T, Enomoto Y, Fukuhara H, et al. (January 2010). "Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer". Aktuelle Urologie. 41 (Suppl 1): S34–S40. doi:10.1055/s-0029-1224657. PMID 20094950. S2CID 7710924.
- ↑ Sayed Y, Taxel P (December 2003). "The use of estrogen therapy in men". Current Opinion in Pharmacology. 3 (6): 650–654. doi:10.1016/j.coph.2003.07.004. PMID 14644018.
- 1 2 Hedlund PO, Henriksson P (March 2000). "Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study". Urology. 55 (3): 328–333. doi:10.1016/s0090-4295(99)00580-4. PMID 10699602.
- ↑ Shimizu TS, Shibata Y, Jinbo H, Satoh J, Yamanaka H (1995). "Estramustine phosphate for preventing flare-up in luteinizing hormone-releasing hormone analogue depot therapy". European Urology. 27 (3): 192–195. doi:10.1159/000475159. PMID 7541359.
- 1 2 3 4 Muller NF, Dessing RP, eds. (19 June 1998). European Drug Index: European Drug Registrations (Fourth ed.). CRC Press. pp. 245, 454. ISBN 978-3-7692-2114-5.
- ↑ Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 2153–. ISBN 978-0-7817-1750-2.
- ↑ Tammela T (November 2004). "Endocrine treatment of prostate cancer". The Journal of Steroid Biochemistry and Molecular Biology. 92 (4): 287–295. doi:10.1016/j.jsbmb.2004.10.005. PMID 15663992. S2CID 25425351.
- ↑ Cox RL, Crawford ED (December 1995). "Estrogens in the treatment of prostate cancer". The Journal of Urology. 154 (6): 1991–1998. doi:10.1016/S0022-5347(01)66670-9. PMID 7500443.
- 1 2 Lubiniecki GM, Berlin JA, Weinstein RB, Vaughn DJ (December 2004). "Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis". Cancer. 101 (12): 2755–2759. doi:10.1002/cncr.20673. PMID 15536625. S2CID 21465413.
- ↑ Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, et al. (November 2007). "Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data". The Lancet. Oncology. 8 (11): 994–1000. doi:10.1016/S1470-2045(07)70284-X. PMID 17942366.
- ↑ Petrioli R, Roviello G, Fiaschi AI, Laera L, Bianco V, Ponchietti R, et al. (October 2015). "Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer". Clinical Genitourinary Cancer. 13 (5): 441–446. doi:10.1016/j.clgc.2015.03.004. PMID 25920994.
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Gunnarsson PO, Forshell GP (June 1984). "Clinical pharmacokinetics of estramustine phosphate". Urology. 23 (6 Suppl): 22–27. doi:10.1016/S0090-4295(84)80093-X. PMID 6375076.
- 1 2 Alexander NC, Hancock AK, Masood MB, Peet BG, Price JJ, Turner RL, et al. (March 1979). "Estracyt in advanced carcinoma of the breast: a phase II study". Clinical Radiology. 30 (2): 139–147. doi:10.1016/S0009-9260(79)80133-6. PMID 86404.
- 1 2 Daponte D, Sylvester R, De Pauw M, Fryszman A, Smith RM, Smith PH (August 1983). "Change in white cell count during treatment of advanced cancer of the prostate with estramustine phosphate and with stilboestrol". British Journal of Urology. 55 (4): 408–412. doi:10.1111/j.1464-410X.1983.tb03333.x. PMID 6349745.
- ↑ "Emcyt estramustine phosphate sodium capsules" (PDF). FDA. Retrieved 14 March 2022.
- 1 2 3 4 5 6 7 8 9 10 Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 502–503. ISBN 978-1-4757-2085-3.
- 1 2 Wang LG, Liu XM, Kreis W, Budman DR (May 1998). "Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor". Biochemical Pharmacology. 55 (9): 1427–1433. doi:10.1016/S0006-2952(97)00657-6. PMID 10076535.
- 1 2 Van Poppel H, Werbrouck PW, Baert L (1990). "Effect of estramustine phosphate on free androgens. A comparative study of the effect of orchiectomy and estramustine phosphate on free androgens in patients with prostatic cancer". Acta Urologica Belgica. 58 (4): 89–95. PMID 2093302.
- 1 2 3 Karr JP, Wajsman Z, Kirdani RY, Murphy GP, Sandberg AA (August 1980). "Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients". The Journal of Urology. 124 (2): 232–236. doi:10.1016/S0022-5347(17)55383-5. PMID 7190620.
- ↑ Olson KB, Pienta KJ (May 2000). "Recent advances in chemotherapy for advanced prostate cancer". Current Urology Reports. 1 (1): 48–56. doi:10.1007/s11934-000-0035-z. PMID 12084341. S2CID 31084737.
- 1 2 Daehlin L, Damber JE, von Schoultz B, Bergman B (August 1986). "The oestrogenic effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate in patients with prostatic carcinoma. A comparative study of oestrogen sensitive liver proteins, gonadotrophins and prolactin". British Journal of Urology. 58 (4): 412–416. doi:10.1111/j.1464-410X.1986.tb09095.x. PMID 3092893.
- ↑ Fredholm, B., Jensen, G., Lindskog, M., & Muntzing, J. (1974, January). Effects of estramustine phosphate (Estracyt) on growth of DMBA-induced mammary tumors in rats. In Acta Pharmacologica et Toxicologica (Vol. 35, pp. 28-28). 35 Norre Sogade, PO Box 2148, DK-1016 Copenhagen, Denmark: Munksgaard Int Publ Ltd.
- 1 2 3 Punzi JS, Duax WL, Strong P, Griffin JF, Flocco MM, Zacharias DE, et al. (March 1992). "Molecular conformation of estramustine and two analogues". Molecular Pharmacology. 41 (3): 569–576. PMID 1545778.
- 1 2 Hauser AR, Merryman R (May 1984). "Estramustine phosphate sodium". Drug Intelligence & Clinical Pharmacy. 18 (5): 368–374. doi:10.1177/106002808401800502. PMID 6373212. S2CID 25303747.
- ↑ Tew KD, Stearns ME (1989). "Estramustine--a nitrogen mustard/steroid with antimicrotubule activity". Pharmacology & Therapeutics. 43 (3): 299–319. doi:10.1016/0163-7258(89)90012-0. PMID 2682681.
- ↑ Cavalli F, Kaye SB, Hansen HH, Armitage JO, Piccart-Gebhart M, eds. (12 September 2009). Textbook of Medical Oncology (Fourth ed.). CRC Press. pp. 442–. ISBN 978-0-203-09289-7.
- ↑ Gunnarsson O, Andersson SB, Johansson SA (1983). "The hydrolysis of estramustine phosphate; in vitro studies". European Journal of Drug Metabolism and Pharmacokinetics. 8 (4): 395–402. doi:10.1007/BF03188772. PMID 6673977. S2CID 22105700.
- 1 2 Ozeki T, Takeuchi M, Suzuki M, Kitamura T, Takayanagi R, Yokoyama H, Yamada Y (October 2009). "Single nucleotide polymorphisms of 17beta-hydroxysteroid dehydrogenase type 7 gene: mechanism of estramustine-related adverse reactions?". International Journal of Urology. 16 (10): 836–841. doi:10.1111/j.1442-2042.2009.02374.x. PMID 19735314. S2CID 38350076.
- 1 2 Suzuki M, Muto S, Hara K, Ozeki T, Yamada Y, Kadowaki T, et al. (February 2005). "Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients". International Journal of Urology. 12 (2): 166–172. doi:10.1111/j.1442-2042.2005.01004.x. PMID 15733111. S2CID 71166897.
- ↑ Gate L, Tew KD (2011). "Alkylating Agents". Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. Cancer Growth and Progression. Springer. pp. 61–85. doi:10.1007/978-90-481-9704-0_4. ISBN 978-90-481-9703-3.
- ↑ "Estradiol" (PDF). Abbott Laboratories. November 2009.
- ↑ Loftsson T (25 January 2014). Drug Stability for Pharmaceutical Scientists. Academic Press. pp. 77–. ISBN 978-0-12-411562-0.
- ↑ Bernal S (21 August 1997). Drug Resistance in Oncology. CRC Press. pp. 287–. ISBN 978-1-4200-0209-6.
- ↑ Murff SJ (20 February 2012). Safety and Health Handbook for Cytotoxic Drugs. Government Institutes. pp. 89–. ISBN 978-1-60590-705-5.
- 1 2 "Estramustine phosphate". PubChem. U.S. National Library of Medicine.
- ↑ Figg WD, Chau CH, Small EJ (14 September 2010). Drug Management of Prostate Cancer. Springer Science & Business Media. pp. 402–. ISBN 978-1-60327-829-4.
- ↑ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 114–. ISBN 978-94-011-4439-1.
- ↑ "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 29 January 2017.
- ↑ Sweetman, S, ed. (12 February 2013). "Estramustine Sodium Phosphate". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 8 February 2014.
Further reading
- Tew KD (September 1983). "The mechanism of action of estramustine". Seminars in Oncology. 10 (3 Suppl 3): 21–26. PMID 6364362.
- Hoisaeter PA, Bakke A (September 1983). "Estramustine phosphate (Estracyt): experimental and clinical studies in Europe". Seminars in Oncology. 10 (3 Suppl 3): 27–33. PMID 6364363.
- Sandberg AA (September 1983). "Metabolic aspects and actions unique to Estracyt". Seminars in Oncology. 10 (3 Suppl 3): 3–15. PMID 6364364.
- Haukaas SA (1984). "Immunological effects of diethylstilbestrol and estramustine phosphate". Scandinavian Journal of Urology and Nephrology. Supplementum. 83: 1–32. PMID 6387896.
- Hauser AR, Merryman R (May 1984). "Estramustine phosphate sodium". Drug Intelligence & Clinical Pharmacy. 18 (5): 368–374. doi:10.1177/106002808401800502. PMID 6373212. S2CID 25303747.
- Sandberg AA (June 1984). "Metabolic parameters of Estracyt pertinent to its effects in prostatic cancer". Urology. 23 (6 Suppl): 11–21. doi:10.1016/S0090-4295(84)80092-8. PMID 6375075.
- Gunnarsson PO, Forshell GP (June 1984). "Clinical pharmacokinetics of estramustine phosphate". Urology. 23 (6 Suppl): 22–27. doi:10.1016/S0090-4295(84)80093-X. PMID 6375076.
- Forsgren B, Björk P (June 1984). "Specific binding of estramustine to prostatic proteins". Urology. 23 (6 Suppl): 34–38. doi:10.1016/S0090-4295(84)80095-3. PMID 6375077.
- Kalland T, Haukaas SA (June 1984). "Immunologic effects of estramustine phosphate". Urology. 23 (6 Suppl): 39–45. doi:10.1016/S0090-4295(84)80096-5. PMID 6375078.
- Høisaeter PA (June 1984). "Mode of action of Emcyt". Urology. 23 (6 Suppl): 46–48. doi:10.1016/S0090-4295(84)80097-7. PMID 6375079.
- Müntzing J, Gunnarsson K (June 1984). "Preclinical pharmacology and toxicology of estramustine phosphate". Urology. 23 (6 Suppl): 6–10. doi:10.1016/S0090-4295(84)80091-6. PMID 6375082.
- Slack NH, Murphy GP (June 1984). "Clinical toxicity and long-term results of Emcyt therapy for prostate cancer". Urology. 23 (6 Suppl): 73–77. doi:10.1016/S0090-4295(84)80103-X. PMID 6375085.
- Hedlund PO (1985). "Mode of action of estramustine phosphate in hormone dependent and hormone non-dependent prostate cancer". Progress in Clinical and Biological Research. 185A: 197–202. PMID 3898129.
- Hedlund PO (1987). "Estracyt--mode of action and clinical experience". Progress in Clinical and Biological Research. 243B: 215–219. PMID 3309981.
- Murphy GP (1987). "A current review of the clinical experience with Estracyt". Progress in Clinical and Biological Research. 243B: 221–225. PMID 3309982.
- Forsgren B (1988). "Estramustine-binding protein in rat and human prostate". Scandinavian Journal of Urology and Nephrology. Supplementum. 107: 56–58. PMID 3287598.
- Tew KD, Stearns ME (1989). "Intracellular effects of estramustine (Estracyt/Emcyt)". Progress in Clinical and Biological Research. 303: 169–175. PMID 2674983.
- Tew KD, Stearns ME (1989). "Estramustine--a nitrogen mustard/steroid with antimicrotubule activity". Pharmacology & Therapeutics. 43 (3): 299–319. doi:10.1016/0163-7258(89)90012-0. PMID 2682681.
- Könyves I (1989). "Estramustine phosphate (Estracyt) in the treatment of prostatic carcinoma". International Urology and Nephrology. 21 (4): 393–397. doi:10.1007/BF02559635. PMID 2693392. S2CID 9727646.
- Benson R, Hartley-Asp B (1990). "Mechanisms of action and clinical uses of estramustine". Cancer Investigation. 8 (3–4): 375–380. doi:10.3109/07357909009012056. PMID 2207764.
- Van Poppel H, Baert L (1991). "The present role of estramustine phosphate in advanced prostate cancer". Progress in Clinical and Biological Research. 370: 323–341. PMID 1924466.
- Janknegt RA (1992). "Estramustine phosphate and other cytotoxic drugs in the treatment of poor prognostic advanced prostate cancer". The Prostate. Supplement. 4: 105–110. doi:10.1002/pros.2990210516. PMID 1574449. S2CID 40562112.
- Tew KD, Glusker JP, Hartley-Asp B, Hudes G, Speicher LA (December 1992). "Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug". Pharmacology & Therapeutics. 56 (3): 323–339. doi:10.1016/0163-7258(92)90023-S. PMID 1301594.
- Kreis W (1995). "Estramustine revisited". Concepts, Mechanisms, and New Targets for Chemotherapy. Cancer Treatment and Research. Vol. 78. Springer. pp. 163–184. doi:10.1007/978-1-4615-2007-8_8. ISBN 978-1-4613-5829-9. PMID 8595142.
- Perry CM, McTavish D (July 1995). "Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer". Drugs & Aging. 7 (1): 49–74. doi:10.2165/00002512-199507010-00006. PMID 7579781. S2CID 36725810.
- Hudes G (February 1997). "Estramustine-based chemotherapy". Seminars in Urologic Oncology. 15 (1): 13–19. PMID 9050135.
- Bergenheim AT, Henriksson R (February 1998). "Pharmacokinetics and pharmacodynamics of estramustine phosphate". Clinical Pharmacokinetics. 34 (2): 163–172. doi:10.2165/00003088-199834020-00004. PMID 9515186. S2CID 1943973.
- Kitamura T (February 2001). "Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer". International Journal of Urology. 8 (2): 33–36. doi:10.1046/j.1442-2042.2001.00254.x. PMID 11240822. S2CID 43384150.
- Ravery V, Fizazi K, Oudard S, Drouet L, Eymard JC, Culine S, et al. (December 2011). "The use of estramustine phosphate in the modern management of advanced prostate cancer". BJU International. 108 (11): 1782–1786. doi:10.1111/j.1464-410X.2011.10201.x. PMID 21756277. S2CID 33456591.
- Qin Z, Li X, Zhang J, Tang J, Han P, Xu Z, et al. (September 2016). "Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis". Medicine. 95 (39): e4801. doi:10.1097/MD.0000000000004801. PMC 5265899. PMID 27684806.